Latest Tanezumab Stories

2013-12-30 08:25:34

LONDON, Dec. 30, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Interstitial Cystitis (Painful Bladder Syndrome) Global Clinical Trials Review, H2, 2013Interstitial Cystitis (Painful Bladder Syndrome) Global Clinical Trials Review, H2, 2013 SummaryGlobalData's clinical trial report, "Interstitial Cystitis (Painful Bladder Syndrome) Global Clinical Trials Review, H2, 2013" provides data on the Interstitial Cystitis (Painful Bladder Syndrome)...

2010-09-30 17:14:58

But for small number, joints got worse and drug development was put on hold A phase II clinical trial of the first new type of drug for musculoskeletal pain since aspirin shows that it significantly reduces knee pain in osteoarthritis, the most common osteoarthritis pain, according to new research from Northwestern Medicine. However, phase III trials of that drug, tanezumab, have been placed on clinical hold after 16 out of several thousand participants in the new trial developed...

2010-07-19 16:01:00

NEW YORK, July 19 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced, at the request of the U.S. Food and Drug Administration (FDA), the suspension of the chronic low back pain and painful diabetic peripheral neuropathy studies in the clinical program for the investigational compound tanezumab. Investigation of the compound continues in some areas of high unmet medical need, including cancer pain. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ) (Logo:...

2010-06-23 16:20:00

NEW YORK, June 23 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today the suspension of the osteoarthritis clinical program for the investigational compound tanezumab following a request by the U.S. Food and Drug Administration (FDA). The worldwide suspension - which is effective immediately - follows a small number of reports of tanezumab patients experiencing the worsening of osteoarthritis leading to joint replacement. To date, this adverse event has not been observed in...

2010-02-04 05:02:00

SAN ANTONIO, Feb. 4 /PRNewswire-USNewswire/ -- Tanezumab, a humanized monoclonal antibody that targets nerve-growth factor, reduced pain in three common pain conditions, according to the results from three phase two studies presented today in a single poster at the American Academy of Pain Medicine's 26th Annual Meeting. Researchers from Pfizer presented the results from three separate randomized, double-blind, placebo-controlled, clinical trials of tanezumab involving a total of 725...

Word of the Day
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'